Abrams P H, Choa R G, Gaches C G, Ashken M H, Green N A
Br J Urol. 1981 Dec;53(6):585-7. doi: 10.1111/j.1464-410x.1981.tb03266.x.
Sixty patients with recurrent superficial bladder tumours (Ta or T1) entered an open controlled trial of single dose Adriamycin. After transurethral resection of tumor recurrences, patients were alternately allocated to the control group or to the Adriamycin group, who received an instillation of 50 mg of Adriamycin in 50 ml of saline for 30 min. Six months later all patients were readmitted for endoscopy. In the Adriamycin group significantly more patients showed a decrease in the number of recurrent papillomas (72%) than in the control group (39%). This study shows that the use of adjuvant chemotherapy in the form of single dose Adriamycin is effective in reducing tumour recurrence.
60例复发性浅表性膀胱肿瘤（Ta或T1）患者进入了单剂量阿霉素的开放对照试验。经尿道切除肿瘤复发灶后，患者被交替分配到对照组或阿霉素组，阿霉素组患者接受50mg阿霉素溶于50ml生理盐水中灌注30分钟。6个月后，所有患者再次入院接受内镜检查。阿霉素组中显示复发性乳头状瘤数量减少的患者比例（72%）显著高于对照组（39%）。本研究表明，以单剂量阿霉素形式使用辅助化疗在减少肿瘤复发方面是有效的。
